# Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

> **NCT05465954** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 54 (estimated)

## Conditions studied

- High Grade Astrocytic Tumor
- Recurrent Glioblastoma, IDH-Wildtype
- Recurrent Gliosarcoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **BIOLOGICAL:** Efineptakin alfa
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT05465954
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-24
- **Primary completion:** 2027-10-15
- **Final completion:** 2028-10-15
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05465954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05465954, "Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05465954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*